Research gaps in defining the biological link between HIV risk and hormonal contraception

Kerry J. Murphy, Susan C. Irvin, Betsy Herold

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Epidemiologic data suggest an association between depot medroxyprogesterone acetate (DMPA), a progesterone-based hormonal contraceptive, and increased risk of HIV acquisition and transmission. DMPA is highly effective and is among the most commonly used form of hormonal contraception in areas of high HIV prevalence. Thus, defining the biological mechanisms that contribute to the potential negative synergy between DMPA and HIV is key and may facilitate the identification of alternative contraceptive strategies. Proposed mechanisms include thinning or disruption of the cervicovaginal epithelial barrier, induction of mucosal inflammation, interference with innate and adaptive soluble and cellular immune responses, and/or alterations in the vaginal microbiome. DMPA may also indirectly increase the risk of HIV by promoting genital herpes or other sexually transmitted infections. However, there is a paucity of rigorous in vitro, animal model and clinical data to support these potential mechanisms highlighting the need for future research.

Original languageEnglish (US)
Pages (from-to)228-235
Number of pages8
JournalAmerican Journal of Reproductive Immunology
Volume72
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Medroxyprogesterone Acetate
Contraception
HIV
Contraceptive Agents
Research
Herpes Genitalis
Microbiota
Adaptive Immunity
Sexually Transmitted Diseases
Cellular Immunity
Progesterone
Animal Models
Inflammation

Keywords

  • Depo-Provera
  • Female genital tract
  • HIV
  • Hormonal contraception
  • Mucosal immunity

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Research gaps in defining the biological link between HIV risk and hormonal contraception. / Murphy, Kerry J.; Irvin, Susan C.; Herold, Betsy.

In: American Journal of Reproductive Immunology, Vol. 72, No. 2, 2014, p. 228-235.

Research output: Contribution to journalArticle

@article{d4fc38715cc14c5b955e6da54cf9c75a,
title = "Research gaps in defining the biological link between HIV risk and hormonal contraception",
abstract = "Epidemiologic data suggest an association between depot medroxyprogesterone acetate (DMPA), a progesterone-based hormonal contraceptive, and increased risk of HIV acquisition and transmission. DMPA is highly effective and is among the most commonly used form of hormonal contraception in areas of high HIV prevalence. Thus, defining the biological mechanisms that contribute to the potential negative synergy between DMPA and HIV is key and may facilitate the identification of alternative contraceptive strategies. Proposed mechanisms include thinning or disruption of the cervicovaginal epithelial barrier, induction of mucosal inflammation, interference with innate and adaptive soluble and cellular immune responses, and/or alterations in the vaginal microbiome. DMPA may also indirectly increase the risk of HIV by promoting genital herpes or other sexually transmitted infections. However, there is a paucity of rigorous in vitro, animal model and clinical data to support these potential mechanisms highlighting the need for future research.",
keywords = "Depo-Provera, Female genital tract, HIV, Hormonal contraception, Mucosal immunity",
author = "Murphy, {Kerry J.} and Irvin, {Susan C.} and Betsy Herold",
year = "2014",
doi = "10.1111/aji.12209",
language = "English (US)",
volume = "72",
pages = "228--235",
journal = "American Journal of Reproductive Immunology and Microbiology",
issn = "1046-7408",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Research gaps in defining the biological link between HIV risk and hormonal contraception

AU - Murphy, Kerry J.

AU - Irvin, Susan C.

AU - Herold, Betsy

PY - 2014

Y1 - 2014

N2 - Epidemiologic data suggest an association between depot medroxyprogesterone acetate (DMPA), a progesterone-based hormonal contraceptive, and increased risk of HIV acquisition and transmission. DMPA is highly effective and is among the most commonly used form of hormonal contraception in areas of high HIV prevalence. Thus, defining the biological mechanisms that contribute to the potential negative synergy between DMPA and HIV is key and may facilitate the identification of alternative contraceptive strategies. Proposed mechanisms include thinning or disruption of the cervicovaginal epithelial barrier, induction of mucosal inflammation, interference with innate and adaptive soluble and cellular immune responses, and/or alterations in the vaginal microbiome. DMPA may also indirectly increase the risk of HIV by promoting genital herpes or other sexually transmitted infections. However, there is a paucity of rigorous in vitro, animal model and clinical data to support these potential mechanisms highlighting the need for future research.

AB - Epidemiologic data suggest an association between depot medroxyprogesterone acetate (DMPA), a progesterone-based hormonal contraceptive, and increased risk of HIV acquisition and transmission. DMPA is highly effective and is among the most commonly used form of hormonal contraception in areas of high HIV prevalence. Thus, defining the biological mechanisms that contribute to the potential negative synergy between DMPA and HIV is key and may facilitate the identification of alternative contraceptive strategies. Proposed mechanisms include thinning or disruption of the cervicovaginal epithelial barrier, induction of mucosal inflammation, interference with innate and adaptive soluble and cellular immune responses, and/or alterations in the vaginal microbiome. DMPA may also indirectly increase the risk of HIV by promoting genital herpes or other sexually transmitted infections. However, there is a paucity of rigorous in vitro, animal model and clinical data to support these potential mechanisms highlighting the need for future research.

KW - Depo-Provera

KW - Female genital tract

KW - HIV

KW - Hormonal contraception

KW - Mucosal immunity

UR - http://www.scopus.com/inward/record.url?scp=84904291192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904291192&partnerID=8YFLogxK

U2 - 10.1111/aji.12209

DO - 10.1111/aji.12209

M3 - Article

VL - 72

SP - 228

EP - 235

JO - American Journal of Reproductive Immunology and Microbiology

JF - American Journal of Reproductive Immunology and Microbiology

SN - 1046-7408

IS - 2

ER -